|

Donanemab Clinical Trials

5 actively recruiting trials across 3 locations

▲ +1 trial since August 2026

Also known as: (LY3002813), LY3002813

Pipeline

Phase 2: 1Phase 3: 2Phase 2/3: 1

Top Sponsors

  • Eli Lilly and Company4
  • Banner Health1

Indications

  • Alzheimer's Disease5
  • Alzheimer Disease3
  • Autosomal Dominant Alzheimers Disease1
  • Plaque, Amyloid1
  • Synucleinopathies1

Other2 trials

A Study of Donanemab, RG6289, or the Combination of Donanemab and RG6289 in Presenilin 1 (PSEN1) E280A Mutation Carriers for the Treatment of Autosomal-Dominant Alzheimer's Disease
Phase 2/3
Donanemab (LY3002813) Trial in Chinese Participants With Cognitively Unimpaired (Preclinical) Alzheimer's Disease
Phase 3

Huntsville, Alabama1 trial

A Real-World Comparative Study of Donanemab (LY3002813) Plus Usual Care Versus Usual Care Alone in US Participants With Early Symptomatic Alzheimer's Disease

Rehabilitation & Neurological Services

Chandler, Arizona1 trial

A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)

TrialSphere Corp

Phase 2

Phoenix, Arizona1 trial

A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).

Banner Alzheimer's Institute

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.